Prevention of Early Alzheimer's Disease by Erinacine A-EnrichedHericium erinaceusMycelia Pilot Double-Blind Placebo-Controlled Study

doi:10.3389/fnagi.2020.00155

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24681

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24681

题名:	Prevention of Early Alzheimer's Disease by Erinacine A-EnrichedHericium erinaceusMycelia Pilot Double-Blind Placebo-Controlled Study
作者:	Li, IC;Chang, HH;Lin, CH;Chen, WP;Lu, TH;Lee, LY;Chen, YW;Chen, YP;Chen, CC;Lin, DPC
关键词:	erinacine A-enrichedH;erinaceusmycelia;Alzheimer's disease;pilot study;prevention;magnetic resonance imaging
日期:	2020
上传时间:	2022-08-09T08:06:17Z (UTC)
出版者:	FRONTIERS MEDIA SA
ISSN:	1663-4365
摘要:	Objective To investigate the efficacy and safety of threeH. erinaceusmycelia (EAHE) capsules (350 mg/capsule; containing 5 mg/g erinacine A active ingredient) per day for the treatment of patients with mild Alzheimer's Disease (AD). Methods This study comprised a 3-week no-drug screening period, followed by a 49-week double-blind treatment period with 2-parallel groups in which eligible patients were randomized to either three 5 mg/g EAHE mycelia capsules per day or identical appearing placebo capsules. Cognitive assessments, ophthalmic examinations, biomarker collection, and neuroimaging were followed throughout the study period. Results After 49 weeks of EAHE intervention, a significant decrease in Cognitive Abilities Screening Instrument score was noted in the placebo group, a significant improvement in Mini-Mental State Examination score was observed in the EAHE group and a significant Instrumental Activities of Daily Living score difference were found between the two groups. In addition, EAHE group achieved a significantly better contrast sensitivity when compared to the placebo group. Moreover, only the placebo group observed significantly lowered biomarkers such as calcium, albumin, apolipoprotein E4, hemoglobin, and brain-derived neurotrophic factor and significantly elevated alpha1-antichymotrypsin and amyloid-beta peptide 1-40 over the study period. Using diffusion tensor imaging, the mean apparent diffusion coefficient (ADC) values from the arcuate fasciculus region in the dominant hemisphere significantly increased in the placebo group while no significant difference was found in the EAHE group in comparison to their baselines. Moreover, ADC values from the parahippocampal cingulum region in the dominant hemisphere significantly decreased in the EAHE group whereas no significant difference was found in the placebo group when compared to their baselines. Lastly, except for four subjects who dropped out of the study due to abdominal discomfort, nausea, and skin rash, no other adverse events were reported. Conclusion Three 350 mg/g EAHE capsules intervention for 49 weeks demonstrated higher CASI, MMSE, and IADL scores and achieved a better contrast sensitivity in patients with mild AD when compared to the placebo group, suggesting that EAHE is safe, well-tolerated, and may be important in achieving neurocognitive benefits.
URI:	http://dx.doi.org/10.3389/fnagi.2020.00155 https://www.webofscience.com/wos/woscc/full-record/WOS:000542976300001 https://ir.csmu.edu.tw:8080/handle/310902500/24681
關聯:	FRONTIERS IN AGING NEUROSCIENCE ,2020 ,v12
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	194	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....